Biotie is a biopharmaceutical company focused on products for neurodegenerative and psychiatric disorders. Its best known product to-date is Selincro for alcohol dependence, which received European marketing authorization in 2013. It currently has a number of products in development, including tozadenant for Parkinson's disease and two compounds for cognitive disorders. Biotie Therapies Corp. is headquartered in Turku, Finland. As of April 18, 2016, it operates as a subsidiary of Acorda Therapeutics, Inc.